Analysis of metabolic rewiring in MDR1-overexpressing drug-resistant glioblastoma
Frontiers in Pharmacology · 01.04.2026 · 17
DOI: 10.3389/fphar.2026.1760920 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 01.04.2026. Verfasst von Manendra Singh Tomar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advance Research, Faculty of Medicine, King George's Medical University, Lucknow, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma (GBM) is a primary brain tumor, and temozolomide is the first-line alkylating agent utilized as a chemotherapeutic treatment. Despite major improvements in diagnosis and therapy, patient’s outcomes remain poor, mostly due to acquired temozolomide resistance. ABC transporter-mediated drug efflux is one of the mechanisms that play a crucial role in temozolomide resistance; however, the metabolic mechanisms that sustain MDR1 (ABCB1) activity in GBM remain unknown. Here, we established stable MDR1-overexpressing GBM cells and demonstrated their functional involvement in drug efflux by decreased intracellular doxorubicin accumulation and increased cell viability. Gas chromatography-mass spectrometry-based untargeted metabolomics profiling identified significantly altered metabolites in MDR1-overexpressing cells. Results of multivariate and univariate statistical analysis revealed higher levels of tricarboxylic acid (TCA) cycle intermediates that are associated with enhanced mitochondrial bioenergetics. Pathway enrichment revealed metabolite alterations in the TCA cycle, amino acid, and glutathione metabolism, indicating a coordinated metabolic rewiring potentially linked to increased ATP demand for MDR1 activity. The annexin V staining showed increased apoptotic cell populations upon metformin treatment, supporting the association between mitochondrial metabolism and intracellular drug accumulation. Overall, this study suggests that mitochondrial metabolism is a bioenergetic driver of MDR1 activity, and it could be a potential therapeutic target for overcoming MDR1-mediated drug resistance in GBM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Advance Research, Faculty of Medicine, King George's Medical University, Lucknow, India.
- Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
- Division of Endocrinology and Centre for Research in Anabolic Skeletal Targets in Health and Illness (ASTHI), CSIR-Central Drug Research Institute, Lucknow, India.
- Pharmacology Division, CSIR-Central Drug Research Institute, Lucknow, India.
Zitieren
APA
Tomar, M. S., Shrivastava, A., Prajapati, P., Kulkarni, C., Sadhukhan, S., Gupta, S. K., Chattopadhyay, N., & Lahiri, A. (2026). Analysis of metabolic rewiring in MDR1-overexpressing drug-resistant glioblastoma. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1760920
Vancouver
Tomar MS, Shrivastava A, Prajapati P, Kulkarni C, Sadhukhan S, Gupta SK, et al. Analysis of metabolic rewiring in MDR1-overexpressing drug-resistant glioblastoma. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1760920
BibTeX
@article{Tomar2026,
author = {Tomar, Manendra Singh and Shrivastava, Ashutosh and Prajapati, Priyanka and Kulkarni, Chirag and Sadhukhan, Sreyanko and Gupta, Shashi Kumar and Chattopadhyay, Naibedya and Lahiri, Amit},
title = {Analysis of metabolic rewiring in MDR1-overexpressing drug-resistant glioblastoma},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1760920}
}
EUVIMED